Recombinant Human alpha-Galactosidase A/GLA Protein, CF

Catalog # Availability Size / Price Qty
Recombinant Human alpha-Galactosidase A/GLA Protein Enzyme Activity Diagram.
3 Images
Product Details
Citations (3)
Reviews (2)

Recombinant Human alpha-Galactosidase A/GLA Protein, CF Summary

Product Specifications

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Level
<1.0 EU per 1 μg of the protein by the LAL method.
Measured by its ability to hydrolyze 4-methylumbelliferyl-alpha -D-galactopyranoside. The specific activity is >1,100 pmol/min/μg, as measured under the described conditions.
Chinese Hamster Ovary cell line, CHO-derived human alpha-Galactosidase A/GLA protein
Met1-Leu429, with a C-terminal 6-His tag
Accession #
N-terminal Sequence
Predicted Molecular Mass
46 kDa
45-55 kDa, reducing conditions

Product Datasheets

You must select a language.



Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.


Formulation Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Assay Procedure

  • Assay Buffer: 50 mM Sodium Citrate, 50 mM NaCl, pH 4.0
  • Recombinant Human alpha ‑Galactosidase A/GLA (rhGLA) (Catalog # 6146-GH)
  • Substrate: 4-methylumbelliferyl-alpha -D-galactopyranoside (Sigma, Catalog # M7633), 6.7 mM Stock in DMSO
  • F16 Black Maxisorp Plate (Nunc, Catalog # 475515)
  • Fluorescent Plate Reader (Model: SpectraMax Gemini EM by Molecular Devices) or equivalent
  1. Dilute rhGLA to 4.0 ng/µL in Assay Buffer.
  2. Dilute Substrate to 800 µM in Assay Buffer.
  3. Load into plate 50 µL of 4.0 ng/µL rhGLA, and start the reaction by adding 50 µL of 800 µM Substrate. Include a Substrate Blank containing 50 µL Assay Buffer and 50 µL Substrate.
  4. Read at excitation and emission wavelengths of 365 nm and 445 nm, respectively, in kinetic mode for 5 minutes.
  5. Calculate the specific activity:

     Specific Activity (pmol/min/µg) =

Adjusted Vmax* (RFU/min) x Conversion Factor** (pmol/RFU)
amount of enzyme (µg)

     *Adjusted for Substrate Blank
     **Derived using calibration standard 4-Methylumbelliferone (Sigma, Catalog # M1381).

Per Well:
  • rhGLA: 0.200 µg
  • Substrate: 400 µM

Scientific Data

Enzyme Activity View Larger

Recombinant Human alpha-Galactosidase A/GLA Protein, CF (Catalog # 6146-GH) hydrolyses the terminal alpha -galactosyl moieties from glycolipids and glycoproteins. The common ceramide trihexoside substrate is displayed in the diagram.

Enzyme Activity View Larger

Recombinant Human alpha-Galactosidase A/GLA Protein, CF (Catalog # 6146-GH) is measured by its ability to hydrolyze 4-methylumbelliferyl-alpha -D-galactopyranoside.

SDS-PAGE View Larger

2 μg/lane of Recombinant Human alpha ‑Galactosidase A/GLA Protein (Catalog # 6146-GH) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 45-55 kDa.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Background: alpha-Galactosidase A/GLA

Human alpha -Galactosidase A is a homodimeric glycoprotein that can release terminal alpha -galactosyl moieties from glycolipids and glycoproteins and catalyze the hydrolysis of melibiose into galactose and glucose (1). It is a lysosomal enzyme and is responsible for degradation of glycolipid globotriaosylceramide (Gb3) (Gal alpha 1‑4Gal beta 1‑4Glc beta ‑ceramide). Mutations in this gene cause Fabry disease, an X-linked hereditary lysosomal storage disease with the accumulation of Gb3 in the walls of small blood vessels, nerves, dorsal root ganglia, renal glomerular and tubular epithelial cells, and cardiomyocytes (2, 3). Inability to prevent the glycosphingolipid deposition can cause hypertension, strokes, heart attack and progressive renal failure (4). Current treatment for Fabry disease is enzyme replacement therapy using intravenously delivered recombinant alpha -Galactosidase A (5, 6).

  1. Ioannou, Y.A. et al. (1998) Biochem. J. 332:789.
  2. Koide, T. et al. (1990) FEBS Lett. 259:353.
  3. Ioannou Y.A, et al. (1992) J. Cell Biol. 119:1137.
  4. Germain, D.P. (2002) Expert. Opin. Investig. Drugs. 11:1467.
  5. Barngrover, D. (2003) J. Biotechnol. 95:280.
  6. Mignani, R. and Cagnoli, L. (2004) J. Nephrol. 17:354.
Entrez Gene IDs
2717 (Human)
Alternate Names
agalsidase alfa; Agalsidase alpha; Agalsidase; Alpha-D-galactosidase A; alpha-D-galactoside galactohydrolase 1; Alpha-D-galactoside galactohydrolase; alpha-gal A; alpha-galactosidase A; EC 3.2.1; EC; GALA; galactosidase, alpha; GLA; Melibiase

Citations for Recombinant Human alpha-Galactosidase A/GLA Protein, CF

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

3 Citations: Showing 1 - 3
Filter your results:

Filter by:

  1. Development of Lanzyme as the Potential Enzyme Replacement Therapy Drug for Fabry Disease
    Authors: M Deng, H Zhou, Z Liang, Z Li, Y Wang, W Guo, AY Zhao, F Li, Y Mu, AZ Zhao
    Biomolecules, 2022-12-27;13(1):.
    Species: N/A
    Sample Types: Recombinant Protein
    Applications: Western Blot Control
  2. Quantifying lysosomal glycosidase activity within cells using bis-acetal substrates
    Authors: S Cecioni, RA Ashmus, PA Gilormini, S Zhu, X Chen, X Shan, C Gros, MC Deen, Y Wang, R Britton, DJ Vocadlo
    Nature Chemical Biology, 2022-02-24;18(3):332-341.
    Species: Human
    Sample Types: Whole Cells
    Applications: Bioassay
  3. The New Pharmacological Chaperones PBXs Increase alpha-Galactosidase A Activity in Fabry Disease Cellular Models
    Authors: P Besada, M Gallardo-G, T Pérez-Márq, L Patiño-Álv, S Pantano, C Silva-Lópe, C Terán, A Arévalo-Gó, A Ruz-Zafra, J Fernández-, S Ortolano
    Biomolecules, 2021-12-10;11(12):.
    Species: Human
    Sample Types: Protein
    Applications: Bioassay


No product specific FAQs exist for this product, however you may

View all Proteins and Enzyme FAQs

Reviews for Recombinant Human alpha-Galactosidase A/GLA Protein, CF

Average Rating: 5 (Based on 2 Reviews)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used Recombinant Human alpha-Galactosidase A/GLA Protein, CF?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Recombinant Human alpha-Galactosidase A/GLA Protein, CF
By Anonymous on 05/23/2016
Application: Enzymatic activity in vitro

Recombinant Human alpha-Galactosidase A/GLA Protein, CF
By Anonymous on 05/17/2016
Application: Enzymatic activity in vitro